The Roles of Insulin-Like Growth Factors in Mesenchymal Stem Cell Niche

Youssef, Amer; Aboalola, Doaa; Han, V. K. M.

doi:10.1155/2017/9453108

Cited by 85 publications

(82 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, a three‐dimensional culture of MSCs on biomaterials that promote cell–cell interactions was shown to enhance the paracrine effects of MSCs on cultured myoblasts . MSCs also enhance their secretory properties when stimulated with growth factors such as IGF‐1 and VEGF . When delivered in vivo using a biomaterial scaffold that released these factors, MSCs showed a tremendous potential to resolve severe muscle injury by reducing scar tissue, promoting angiogenesis, and stimulating the formation of new myofibers …”

Section: Advances In Treatment Of Local Muscle Injuriesmentioning

confidence: 99%

“…174 MSCs also enhance their secretory properties when stimulated with growth factors such as IGF-1 and VEGF. 175 When delivered in vivo using a biomaterial scaffold that released these factors, MSCs showed a tremendous potential to resolve severe muscle injury by reducing scar tissue, promoting angiogenesis, and stimulating the formation of new myofibers. 91 Enhancing cellular function via physical, chemical, biological, or structural cues is a relatively new paradigm in cell therapy.…”

Section: Drawbacks and Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Cell therapy to improve regeneration of skeletal muscle injuries

Qazi

Duda

Ort

et al. 2019

J cachexia sarcopenia muscle

106

128

View full text Add to dashboard Cite

Diseases that jeopardize the musculoskeletal system and cause chronic impairment are prevalent throughout the Western world. In Germany alone, ~1.8 million patients suffer from these diseases annually, and medical expenses have been reported to reach 34.2bn Euros. Although musculoskeletal disorders are seldom fatal, they compromise quality of life and diminish functional capacity. For example, musculoskeletal disorders incur an annual loss of over 0.8 million workforce years to the German economy. Among these diseases, traumatic skeletal muscle injuries are especially problematic because they can occur owing to a variety of causes and are very challenging to treat. In contrast to chronic muscle diseases such as dystrophy, sarcopenia, or cachexia, traumatic muscle injuries inflict damage to localized muscle groups. Although minor muscle trauma heals without severe consequences, no reliable clinical strategy exists to prevent excessive fibrosis or fatty degeneration, both of which occur after severe traumatic injury and contribute to muscle degeneration and dysfunction. Of the many proposed strategies, cell‐based approaches have shown the most promising results in numerous pre‐clinical studies and have demonstrated success in the handful of clinical trials performed so far. A number of myogenic and non‐myogenic cell types benefit muscle healing, either by directly participating in new tissue formation or by stimulating the endogenous processes of muscle repair. These cell types operate via distinct modes of action, and they demonstrate varying levels of feasibility for muscle regeneration depending, to an extent, on the muscle injury model used. While in some models the injury naturally resolves over time, other models have been developed to recapitulate the peculiarities of real‐life injuries and therefore mimic the structural and functional impairment observed in humans. Existing limitations of cell therapy approaches include issues related to autologous harvesting, expansion and sorting protocols, optimal dosage, and viability after transplantation. Several clinical trials have been performed to treat skeletal muscle injuries using myogenic progenitor cells or multipotent stromal cells, with promising outcomes. Recent improvements in our understanding of cell behaviour and the mechanistic basis for their modes of action have led to a new paradigm in cell therapies where physical, chemical, and signalling cues presented through biomaterials can instruct cells and enhance their regenerative capacity. Altogether, these studies and experiences provide a positive outlook on future opportunities towards innovative cell‐based solutions for treating traumatic muscle injuries—a so far unmet clinical need.

show abstract

Section: Advances In Treatment Of Local Muscle Injuriesmentioning

confidence: 99%

Section: Drawbacks and Limitationsmentioning

confidence: 99%

Cell therapy to improve regeneration of skeletal muscle injuries

Qazi

Duda

Ort

et al. 2019

J cachexia sarcopenia muscle

106

128

View full text Add to dashboard Cite

show abstract

“…In these stem cells, LOI presumably contributes to an increase in the stem cell pool and thus elevates the chances for a genetic mutation driving the cancerous transformation of these cells (Jelinic & Shaw, ; Leick et al , ). Furthermore, secretion of IGF2, which is encoded by an imprinted gene, was found to be important for hPSCs self‐renewal (Bendall et al , ) as well as for proliferation of several adult stem cells (Barroca et al , ; Youssef et al , ). These results suggest a special role for imprinted genes in regulating stem cell properties, therefore supporting the speculation that LOI might promote hPSC growth and survival in culture.…”

Section: Introductionmentioning

confidence: 99%

Epigenetic aberrations in human pluripotent stem cells

Bar

Benvenisty

2019

The EMBO Journal

View full text Add to dashboard Cite

Human pluripotent stem cells (hPSCs) are being increasingly utilized worldwide in investigating human development, and modeling and discovering therapies for a wide range of diseases as well as a source for cellular therapy. Yet, since the first isolation of human embryonic stem cells (hESCs) 20 years ago, followed by the successful reprogramming of human‐induced pluripotent stem cells (hiPSCs) 10 years later, various studies shed light on abnormalities that sometimes accumulate in these cells in vitro. Whereas genetic aberrations are well documented, epigenetic alterations are not as thoroughly discussed. In this review, we highlight frequent epigenetic aberrations found in hPSCs, including alterations in DNA methylation patterns, parental imprinting, and X chromosome inactivation. We discuss the potential origins of these abnormalities in hESCs and hiPSCs, survey the different methods for detecting them, and elaborate on their potential consequences for the different utilities of hPSCs.

show abstract

“…It was reported that BMSCs express and secrete IGF-I and/or IGF-II in vitro and ectopic IGF-I enhances their proliferation. 1 However, roles of IGF-I in BMSC proliferation still remain elusive, 18 and various concentrations of exogenous IGF-I did not affect BMSC proliferation in FBS-containing medium. 18 In the present study, endogenous IGF-I suppresses BMSC proliferation in FBS-containing medium, as 20 In the present study, IGFBP-4 produced stimulatory effects on growth of BMSCderived neurospheres as IGF-I did; it can be supposed that IGFBP-4 exerts its beneficial influences on neurosphere growth via enhancing IGF actions.…”

Section: Proliferation Of Npcs Derived From Bmscsmentioning

confidence: 99%

Insulin‐like growth factor binding protein 4 inhibits proliferation of bone marrow mesenchymal stem cells and enhances growth of neurospheres derived from the stem cells

Hao

et al. 2018

Cell Biochemistry & Function

View full text Add to dashboard Cite

Insulin-like growth factor binding protein 4 (IGFBP-4) was reported to trigger cellular senescence and reduce cell growth of bone marrow mesenchymal stem cells (BMSCs), but its contribution to neurogenic differentiation of BMSCs remains unknown. In the present study, BMSCs were isolated from the femur and tibia of young rats to investigate effects of IGFBP-4 on BMSC proliferation and growth of neurospheres derived from BMSCs. Bone marrow mesenchymal stem cell proliferation was assessed using CCK-8 after treatment with IGFBP-4 or blockers of IGF-IR and β-catenin. Phosphorylation levels of Akt, Erk, and p38 in BMSCs were analysed by Western blotting. Bone marrow mesenchymal stem cells were induced into neural lineages in NeuroCult medium; the number and the size of BMSC-derived neurospheres were counted after treatment with IGFBP-4 or the blockers. It was shown that addition of IGFBP-4 inhibited BMSC proliferation and immunodepletion of IGFBP-4 increased the proliferation. The blockade of IGF-IR with AG1024 increased BMSC proliferation and reversed IGFBP-4-induced proliferation inhibition; however, blocking of β-catenin with FH535 did not. p-Erk was significantly decreased in IGFBP-4-treated BMSCs. IGFBP-4 promoted the growth of neurospheres derived from BMSCs, as manifested by the increases in the number and the size of the derived neurospheres. Both AG1024 and FH535 inhibited the formation of NeuroCult-induced neurospheres, but FH535 significantly inhibited the growth of neurospheres in NeuroCult medium with EGF, bFGF, and IGFBP-4. The data suggested that IGFBP-4 inhibits BMSC proliferation through IGF-IR pathway and promotes growth of BMSC-derived neurospheres via stabilizing β-catenin.

show abstract

The Roles of Insulin-Like Growth Factors in Mesenchymal Stem Cell Niche

Cited by 85 publications

References 149 publications

Cell therapy to improve regeneration of skeletal muscle injuries

Cell therapy to improve regeneration of skeletal muscle injuries

Epigenetic aberrations in human pluripotent stem cells

Insulin‐like growth factor binding protein 4 inhibits proliferation of bone marrow mesenchymal stem cells and enhances growth of neurospheres derived from the stem cells

Contact Info

Product

Resources

About